AU2003215622A1 - Use of plag1 and plagl2 in cancer diagnosis and drug screening - Google Patents

Use of plag1 and plagl2 in cancer diagnosis and drug screening

Info

Publication number
AU2003215622A1
AU2003215622A1 AU2003215622A AU2003215622A AU2003215622A1 AU 2003215622 A1 AU2003215622 A1 AU 2003215622A1 AU 2003215622 A AU2003215622 A AU 2003215622A AU 2003215622 A AU2003215622 A AU 2003215622A AU 2003215622 A1 AU2003215622 A1 AU 2003215622A1
Authority
AU
Australia
Prior art keywords
plagl2
plag1
drug screening
cancer diagnosis
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215622A
Inventor
Karen Hensen
Willem Jan Marie Van De Ven
Marianne Leontine Voz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of AU2003215622A1 publication Critical patent/AU2003215622A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AU2003215622A 2002-02-28 2003-02-28 Use of plag1 and plagl2 in cancer diagnosis and drug screening Abandoned AU2003215622A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075814 2002-02-28
EP02075814.0 2002-02-28
PCT/EP2003/002150 WO2003073105A2 (en) 2002-02-28 2003-02-28 Use of plag1 and plagl2 in cancer diagnosis and drug screening

Publications (1)

Publication Number Publication Date
AU2003215622A1 true AU2003215622A1 (en) 2003-09-09

Family

ID=27763408

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215622A Abandoned AU2003215622A1 (en) 2002-02-28 2003-02-28 Use of plag1 and plagl2 in cancer diagnosis and drug screening

Country Status (2)

Country Link
AU (1) AU2003215622A1 (en)
WO (1) WO2003073105A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296309A1 (en) * 2002-09-12 2004-04-30 K.U. Leuven Research & Development Use of plag or plag-inhibitors to diagnose and/or treat disease
EP2130836B1 (en) * 2008-06-03 2013-02-13 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Means and methods for producing zinc fingers and concatemers thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0825198A1 (en) * 1996-08-22 1998-02-25 K.U. Leuven Research & Development Plag gene family and tumorigenesis
WO1999028465A2 (en) * 1997-11-28 1999-06-10 The Regents Of The University Of California Pias molecules that recognize and bind stat proteins and uses thereof
CA2237788A1 (en) * 1998-07-17 2000-01-17 Jeffrey L. Wrana Mammalian fast transcription factor
US6623936B1 (en) * 1999-09-24 2003-09-23 Imgenex Compositions and methods for improved detection and classification of neoplasms
EP1138781A3 (en) * 2000-03-31 2004-07-14 Health Research, Inc. Method for Quantifying DNA binding activity of DNA binding proteins
AUPR204900A0 (en) * 2000-12-14 2001-01-11 Bionomics Limited A novel gene

Also Published As

Publication number Publication date
WO2003073105A3 (en) 2004-04-01
WO2003073105A2 (en) 2003-09-04
WO2003073105A9 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
AU2003900747A0 (en) Diagnosis and treatment of pancreatic cancer
EP1592339A4 (en) Non-invasive determination of direction and rate of change of an analyte
AU2001264559A1 (en) Cancer gene determination and therapeutic screening using signature gene sets
EP1701654A4 (en) Implantable biosensor and methods of use thereof
AU2003232485A1 (en) Neopeptides and methods useful for detection and treatment of cancer
TWI349551B (en) Thiophenepyrimidinone derivatives and their use in therapy
ZA200801829B (en) Novel enhanced processes for drug testing and screening using human tissue
EP1587837A3 (en) Prostate cancer diagnosis and treatment
AU2003205913A1 (en) Materials and methods relating to cancer diagnosis
AU2003298937A1 (en) Heterocyclic compounds, methods of making them and their use in therapy
IL172087A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
AU2003227148A1 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
AU2003300899A1 (en) Genes related to sensitivity and resistance to chemotherapeutic drug treatment
AU2003293013A1 (en) Diagnosing and treating hematopoietic cancers
AU2003218208A1 (en) Methods for diagnosis and prognosis of cancer
AU2003215622A1 (en) Use of plag1 and plagl2 in cancer diagnosis and drug screening
GB0326578D0 (en) Cancer diagnosis and therapy
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2003301160A1 (en) Amplified cancer target genes useful in diagnosis and therapeutic screening
AU2003250912A1 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
SI1639013T1 (en) Pan-kir2dl NK-receptor antibodies and their use in diagnostic and therapy
AU2003271016A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
AU2003295902A1 (en) Methods of therapy and diagnosis using targeting of cells that express p2y10
EP1585955A4 (en) Use of isogenic human cancer cells for high-throughput screening and drug discovery
AU2003209459A1 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase